Page 26 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

OU researcher leads a global trial for a promising new treatment for ovarian cancer

A researcher at University of Oklahoma’s Stephenson Cancer Center is leading a global trial for a promising new treatment for ovarian cancer.The recent clinical ....

Kathleen Moore , University Of Oklahoma Stephenson Cancer Center , Stephenson Cancer Center , United States , Health Medical Pharma , Cancer Treatments , Bradleyj Monk , Gynaecological Cancer , Ovarian Cancer ,

Dr Lucy Langer: How UnitedHealthcare is Enhancing Oncology Pathway Adherence and Promoting Equity

UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence. ....

Lucy Langer ,

2 Minute Medicine Rewind January 29, 2024 | 2 Minute Medicine

Maternal autistic traits and adverse birth outcomes 1. A cohort study found that increased maternal autistic traits were associated with a greater risk of adverse birth outcomes. 2. Women who scored in the clinical range for AQ-J10 were more likely to be young and have higher levels of psychological distress. Evidence Rating Level: 1 (Excellent) ....

National Health Service , Rating Level , Autism Spectrum Quotient Japanese , Covid 19 , Emergency Medicine , Weekly Rewinds ,

Mirtazapine improves caloric intake compared to placebo in patients with advanced non-small cell lung cancer

1. While perceived appetite did not differ between study groups, patients receiving mirtazapine had significantly increased caloric consumption compared with the placebo group. 2. Mirtazapine is well-tolerated, with nightmares being one of the primary significant adverse events, but the difference was insignificant at both the 4- and 8-week follow-up points. Evidence Rating Level: 1 (Excellent) ....

Minute Medicine Inc , Rating Level , Advanced Lung Cancer , Palliative Care , Chronic Disease ,

Low dose olanzapine in non-inferior to standard dose in terms of anti-emetic effect in patients receiving emetogenic chemotherapy

1. Low dose Olanzapine (2.5 mg) demonstrated similar anti-emetic effect to standard dose olanzapine in patients receiving emetogenic chemotherapy 2. Patients in the low-dose group experienced significantly fewer instances of daytime somnolence compared to those who received standard dose Evidence Rating Level: 1 (Excellent) Study Rundown: The present trial was a single-centered trial that compared ....

Rating Level , Anti Emetic , Chemotherapy Induced Nausea , Chronic Disease ,